Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Eli Lilly, clinicians outline Alzheimer’s diagnostics, treatments and policy options to Michigan committee
Summary
Eli Lilly and a Michigan neurologist briefed the Health Policy Committee on recent advances in Alzheimer’s diagnostics (including blood biomarkers), disease‑modifying therapies and proposed state policy responses such as public education and insurance coverage for diagnostic testing.
Laura Cohen, a vice president at Eli Lilly and Company, and Dr. Kara Leahy, a neurologist and director for cognitive disorders at Memorial Healthcare in Owasso, presented to the Health Policy Committee on Alzheimer’s disease, diagnostic advances and possible state policy steps.
Cohen said research investment has produced “disease‑modifying therapies” for some patients in the early stages of Alzheimer’s and pointed to advances in blood biomarker testing that can detect disease biology. She said Alzheimer’s imposes substantial costs: testimony cited roughly 200,000 Michiganders living with Alzheimer’s disease and described state-level direct care costs and unpaid caregiving burdens.
Dr. Leahy told the committee…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
